Fund Raise Details
Sanjivani Paranteral is moving forward with its plan to issue up to 5,00,000 convertible warrants, a move originally proposed in a July 2026 postal ballot. While the initial filing broadly defined the object as future expansion and growth, the company has now specified that ₹5.80 crore from the total proceeds will be directed toward tangible operational enhancements. This clarification comes as part of the in-principle approval process with the exchange, ensuring transparency regarding the deployment of fresh capital into the business's core manufacturing and subsidiary support structures.
Detailed Use of Proceeds
- Incurring capital expenditure of ₹1.57 crore for the acquisition of new machinery and necessary utilities
- Installation of advanced HVAC systems to support pharmaceutical manufacturing standards
- Funding a portion of the ₹9.38 crore commitment toward subsidiary working capital requirements
- Bridging the remaining funding gap for expansion through the company's internal accruals
- Strengthening operational capacity to facilitate long-term growth objectives
Business and Strategic Rationale
The pharmaceutical firm, which specializes in parenteral products such as injectables and IV fluids, is focusing on upgrading its facility infrastructure. The decision to allocate funds to a subsidiary's working capital highlights a strategic push to strengthen its broader group ecosystem. This capital injection is timed with a period of high growth, as the company recently reported a 242.63% sequential increase in net profit for the June 2026 quarter.
By modernizing machinery and ensuring liquidity at the subsidiary level, the management aims to scale production to meet increasing demand in the sterile injectables segment.
Financial and Market Context
Sanjivani Paranteral currently operates with a market capitalization of ₹210.37 crore and maintains a P/E ratio of 19.97, which sits significantly lower than the industry average of 47.65. This valuation gap persists despite a robust quarterly revenue growth of 33.24% year-on-year. While the stock has seen a 29.53% decline over the past year, recent operational performance shows resilience with an operating profit margin of 17.49%.
The proposed warrant issue and subsequent fund deployment are intended to stabilize the balance sheet while fueling the next phase of the company's manufacturing expansion.
